Abbvie Applies for EMA Marketing Authorization for Migraine Drug Atogepant

July 19th, 2022|Categories: Featured, Industry News|Tags: , , , , |

The drugmaker Abbvie has applied to the European Medicines Agency (EMA) for marketing authorization for Atogepant, its prophylactic migrain treatment. Data supporting the application comes from two phase three studies, which showed the drug was well tolerated and was effective at reducing the occurrence of migraines. 

Go to Top